Table III.
COVID-19 treatment. Outcome of univariate analysis regarding the primary endpoint, 30-day mortality
| % | Univariate analysis P | |
|---|---|---|
| Antibiotic | ||
| Azithromycin | 33.3% | 0.004* |
| Antiviral | 48% | |
| Lopinavir | 4.0% | 0.884 |
| Lopinavir+Ritonavir | 41.3% | 0.002* |
| Lopinavir+Ritonavir+Remdesivir | 1.3% | 0.437 |
| Lopinavir+Darunavir | 1.3% | 0.627 |
| Lopinavir (single or combination) | 48.0% | 0.008 |
| Chloroquine/hydroxychloroquine | 68% | 0.623 |
| Chloroquine | 5.3% | 0.626 |
| Hydroxychloroquine | 62.7% | 0.823 |
| Corticosteroids | 34.7% | 0.392 |
| Intravenous immunoglobulins | 0% | - |
| Beta interferon | 12.0% | 0.281 |
| Interleukin-6 receptor antagonist (Tocilizumab) | 22.7% | 0.709 |
| Dialysis | ||
| No | 94.7% | 0.626 |
| <30 postoperative days | 1.3% | 0.373 |
| >30 postoperative days | 0% | - |
| Preoperative treatment | 4.0% | 0.884 |
| Respiratory support | 68.0% | 0.011* |
| Low-flow oxygen therapy | 22.7% | 0.843 |
| High-flow oxygen therapy | 20.0% | 0.403 |
| Noninvasive ventilation | 0% | - |
| Invasive ventilation | 25.3% | 0.032* |
| 1–23 h | 4.0% | 0.884 |
| 24–47 h | 1.3% | 0.373 |
| 48–71 h | 5.3% | 0.017* |
| 72–167 h | 1.3% | 0.373 |
| >167 h | 13.3% | 0.851 |
| ECMO ventilation | 0% | - |
ECMO Extracorporeal membrane oxygenation.
⁎
Statistically significant.